Background-Prerequisite opioid withdrawal symptoms prior to buprenorphine induction are unacceptable to many patients. We assessed whether transdermal buprenorphine minimized withdrawal while bridging to sublingual therapy among hospital inpatients.Methods-Retrospective chart review of (n = 23) inpatients with opioid use disorder or opioid dependence due to chronic pain.Results-Of 23 inpatients, 65% transitioned without symptoms, while 35% experienced mild withdrawal. Ninety-six percent completed planned hospitalizations, with 83% engaged in treatment 4 weeks post-discharge.Discussion and Conclusions-Bridging to sublingual therapy with transdermal buprenorphine patches was feasible without withdrawal symptoms.